Focused On-demand Library for GTPase IMAP family member 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96F15

UPID:

GIMA5_HUMAN

Alternative names:

Immune-associated nucleotide-binding protein 5; Immunity-associated nucleotide 4-like 1 protein; Immunity-associated nucleotide 5 protein; Immunity-associated protein 3

Alternative UPACC:

Q96F15; D3DWZ5; Q6IA75; Q96NE4; Q9NUK9

Background:

GTPase IMAP family member 5, known by alternative names such as Immune-associated nucleotide-binding protein 5, plays a crucial role in T lymphocyte development, CD4/CD8 double-positive thymocytes generation, and GSK3A inhibition. It is pivotal in T cells proliferation, survival of peripheral T cells, NK and NK T-cell development, and liver function maintenance. Additionally, it regulates Ca(2+) homeostasis and mitochondrial DNA segregation in hematopoietic tissues.

Therapeutic significance:

Given its involvement in non-cirrhotic portal hypertension 2, a disorder characterized by portal hypertension without cirrhosis, understanding the role of GTPase IMAP family member 5 could open doors to potential therapeutic strategies for managing this condition and its complications, such as splenomegaly and esophageal varices.